System Accuracy of BGM GL22
Evaluierung Der Systemgenauigkeit Des Blutglucosemonitoring Systems GL22 gemäß DIN EN ISO 15197:2015.
1 other identifier
interventional
113
1 country
1
Brief Summary
This study assesses the system accuracy of a blood glucose monitoring system pursuant to ISO 15197
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable diabetes
Started Nov 2023
Shorter than P25 for not_applicable diabetes
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 7, 2023
CompletedStudy Start
First participant enrolled
November 1, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 22, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
November 24, 2023
CompletedFirst Posted
Study publicly available on registry
November 27, 2023
CompletedNovember 27, 2023
November 1, 2023
21 days
September 7, 2023
November 24, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Analysis of system accuracy based on DIN EN ISO 15197
Assessment of the analytical measurement performance of the blood glucose monitor
Day 1
Study Arms (1)
Subject glucometer measurement
EXPERIMENTALInterventions
blood glucose measurement using finger tip capillary blood using BGM
blood glucose measurement using finger tip capillary blood using reference method
Eligibility Criteria
You may qualify if:
- Male or female patients with hypo-, eu- or hyperglycaemia
- The written informed consent had to be signed
- The volunteers must be older than 18 years
- The volunteers have legal capacity and are able to understand meaning, nature and possible consequences of the procedures involved
You may not qualify if:
- Pregnancy or lactation
- Acute or chronic diseases with the risk of aggravation by the measure
- A current constitution that does not allow participating in the study
- Participation in another study or activity with the blood glucose measuring system evaluated in the present study
- Application of substances listed in Appendix A of DIN EN ISO 15197:2015
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Institut für Diabetes Karlsburg GmbH
Karlsburg, Mecklenburg-Vorpommern, 17495, Germany
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Kerstin Rebrin, PhD
Institut fur Diabetes Karlsburg GmbH
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Dr. Kerstin Rebrin
Study Record Dates
First Submitted
September 7, 2023
First Posted
November 27, 2023
Study Start
November 1, 2023
Primary Completion
November 22, 2023
Study Completion
November 24, 2023
Last Updated
November 27, 2023
Record last verified: 2023-11
Data Sharing
- IPD Sharing
- Will not share